ASH 2020 MCL
Advertisement
In younger patients with mantle cell lymphoma (MCL), pre-transplant MRD status in both bone marrow and peripheral blood ...
Treatment with zanubrutinib was well tolerated and associated with high clinical activity in patients with ...
A novel idiotype (scFv-CCL20) DNA vaccine was associated with favorable perturbation of the immune microenvironment in ...
A study has found that the addition of rituximab to ixazomib, when used as maintenance therapy following autologous ...
A first-line regimen consisting of once-daily ibrutinib plus venetoclax was associated with high rates of undetectable ...
Early initiation of Bruton’s tyrosine kinase inhibitor zanubrutinib in patients with chronic lymphocytic leukemia ...
The use of NSC12, a novel small molecule that specifically halts the FGF/FGFR axis in Waldenstrom macroglobulinemia ...
Patients with chronic lymphocytic leukemia (CLL) who have mild residual lymphadenopathy are more likely to have a ...
A combination regimen consisting of duvelisib and venetoclax was well tolerated, clinically active, and led to ...
Highly selective and irreversible Bruton’s tyrosine kinase inhibitor orelabrutinib was associated with continuous ...
Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were ...
Patients with Waldenstrom macroglobulinemia (WM) who present with characteristics suggestive of a concomitant ...
Since 2006, clinicians treating Waldenstrom macroglobulinemia (WM) have shifted away from using chlorambucil as ...
Final results from the Nordic Lymphoma Group’s phase II PHILEMON trial showed that a combination of ibrutinib, ...
Venetoclax, Lenalidomide, and Rituximab Combo Is Well Tolerated, Shows Promising Efficacy in R/R MCL
A combination treatment approach consisting of venetoclax, lenalidomide, and rituximab was well tolerated and ...In older adult Medicare beneficiaries with CLL, treatment with ibrutinib was associated with a nearly threefold ...
The Chronic Lymphocytic Leukemia (CLL) Comorbidity Index (CLL-CI), which examines endocrine, vascular, and ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
First-line treatment with bortezomib (B) plus dexamethasone, rituximab, and cyclophosphamide (DRC) was well tolerated ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.